US Onychomycosis Market By Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO)), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), & Region for 2024-2031

US Onychomycosis Market Valuation – 2024-2031

The growing demand for the U.S. onychomycosis market, including increased awareness of the condition among the general public and healthcare providers, an aging population, an increase in the prevalence of comorbidities such as diabetes and peripheral arterial disease, and lifestyle factors such as frequent exposure to water, chemicals, or nail trauma. The market size surpass USD 3.69 Billion valued in 2024 to reach a valuation of around USD 6.72 Billion by 2031.

The development of newer and more effective treatment options, such as topical and oral antifungal medicines, laser therapy, and photodynamic therapy, has contributed to the growing demand for onychomycosis therapies in the United States. The rising demand for cost-effective and efficient US onychomycosis is enabling the market grow at a CAGR of 8.60% from 2024 to 2031.

To Get Detailed Analysis: Download Report PDF

US Onychomycosis Market: Definition/ Overview

Onychomycosis, a fungal infection of the nails, particularly the toes, is a prevalent illness in the United States. The US onychomycosis market includes treatments such as oral antifungals, topical medicines, and laser therapy. These therapies are intended to eliminate the infection, restore nail health, and avoid problems such as discomfort, nail deformity, and subsequent infections. Onychomycosis is frequently seen in the elderly, diabetics, and people with weaker immune systems, which increases the need for effective treatments in dermatology clinics, hospitals, and outpatient settings.

The market for onychomycosis in the United States is predicted to grow in the coming decades as the ailment becomes more prevalent, particularly among the elderly and diabetic populations. Advancements in treatment methods, such as combination therapies and non-invasive laser treatments, are expected to drive market expansion.

Rising awareness of personal hygiene and nail health, combined with more accessible treatment options, is projected to fuel demand. Current research into more effective antifungal formulations and the development of less toxic, faster-acting medicines present considerable growth opportunities for the industry.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15766

How will the Increasing Awareness and Healthcare Expenditure Drive the US Onychomycosis Market?

The onychomycosis market in the US is being driven by increased awareness and healthcare expenditure. With healthcare spending in the United States expected to rise by 9.7% to $4.1 trillion by 2020, more resources will be spent on diagnosing and treating illnesses such as onychomycosis. This increase in spending, together with improved public awareness, promotes early detection and treatment, resulting in higher demand for antifungal medicines and novel treatment alternatives, hence driving market expansion.

The expanding geriatric population is likely to propel the U.S. onychomycosis market. Onychomycosis is more common in older persons, and the U.S. Census Bureau predicts that by 2030, the 65-and-over population will reach 73 million, greatly expanding the patient pool for this disease. This demographic transition will enhance demand for effective treatments, accelerating market growth as more elderly people seek diagnosis and treatment for onychomycosis.

How Does the High Treatment Costs Hamper the Growth of the US Onychomycosis Market?

High treatment costs affect the expansion of the US onychomycosis market. Onychomycosis treatments, such as oral antifungals, topical medicines, and laser therapy, can be costly, especially for long-term care. For some patients, particularly those without proper insurance coverage, the high expenses may discourage them from seeking therapy, resulting in underdiagnosis and delayed care. The requirement for constant treatments in severe cases adds to the financial burden, which may limit market expansion despite increased demand for effective solutions.

Side effects impede the expansion of the US onychomycosis market. Many medicines, particularly oral antifungal agents, include side effects such as liver damage, gastrointestinal difficulties, and skin rashes, which may discourage patients from seeking or continuing treatment. These concerns may cause healthcare practitioners and patients to avoid specific therapies, lowering total therapy adoption. Concerns about side effects may drive demand for alternate treatments such as topical solutions and laser therapy, but they may still limit market growth if patients are hesitant to get any treatment at all.

Category-Wise Acumens

What are the Factors that Surge the Demand for the US Onychomycosis Market?

The Distal Subungual Onychomycosis (DSO) segment dominates the US onychomycosis market. Moisture, trauma, and fungal infections are expected to fuel the growth of the Distal Subungual Onychomycosis (DSO) sector in the US onychomycosis market. DSO, the most prevalent form of onychomycosis, is often caused by prolonged moisture contact, nail damage, or fungal infections. Athletes, manual laborers, and people with impaired immune systems are more likely to acquire DSO. As these variables raise the risk of infection, demand for targeted DSO treatments is likely to rise, propelling growth in this category.

The easier diagnosis of Distal Subungual Onychomycosis (DSO) is expected to fuel growth in this section of the US onychomycosis market. DSO is frequently visually obvious, with specific signs such as nail discoloration, depth, and separation, making it easier for healthcare providers to diagnose than other types of onychomycoses. This simplicity of diagnosis allows for faster detection and treatment, encouraging more patients to seek medical care and increasing demand for DSO-specific treatments.

Which Factors Enhance the Use of the US Onychomycosis Market?

Topical antifungal medications experiencing rapid growth in the US onychomycosis market. Antifungal drugs are expected to dominate the topical antifungal medication segment of the US onychomycosis market. Topical antifungals, which include nail lacquers, lotions, and gels, are popular because they are applied directly to the afflicted area, resulting in fewer systemic side effects than oral antifungals. Their tailored activity and low cost make them an enticing option for patients and healthcare providers. As the desire for less intrusive and more targeted treatment choices rises, so will market activity and growth in the topical antifungal medications segment.

Topical antifungal medicines’ success in treating mild to moderate onychomycosis will propel them forward in the US market. Despite being less effective in severe cases than oral therapies, topical medicines are beneficial when taken on a regular basis for less serious infections. Their localized application, lesser risk of systemic side effects, and lower cost make them a popular choice among patients and healthcare professionals, resulting in rising demand and growth in the Topical Antifungal Medications sector.

Gain Access into US Onychomycosis Market Report Methodology

https://www.verifiedmarketresearch.com/select-licence/?rid=15766

Country/Region-wise Acumens

Will the Strong Healthcare Infrastructure in the New York Drive the U.S. Onychomycosis Market?

New York City is the largest market for onychomycosis in the United States. The strong healthcare infrastructure in New York substantially impacts the US onychomycosis market. With approximately 70,000 active physicians, a high concentration of dermatologists (4.0 per 100,000 population, more than the national average), and a projected 7% increase in physician employment, New York, particularly New York City, is well-positioned to meet the growing demand for onychomycosis treatments. The city’s vast population of over 20 million, along with the illness affecting 10-12% of people, results in over 2 million prospective patients, indicating a significant market for therapy. The combination of healthcare capacity and patient demand drives growth in the United States onychomycosis market.

The large population and demographic trends in New York City are major drivers of the US Onychomycosis Market. The city’s massive and increasing population, expected to reach 9 million by 2030, provides a broad patient base. The aging population, which is predicted to reach 1.86 million by 2040, along with a high prevalence of diabetes, which affects around 987,000 adults, drives up the demand for onychomycosis therapies. With a national incidence rate of 10-12%, up to 840,000 New York City people could be impacted, highlighting the city’s significance as a key driver of market expansion and innovation in onychomycosis treatments.

Will the Aging Population Accelerate the  U.S. Onychomycosis Market in California?

California is experiencing the fastest growth in onychomycosis cases and treatments. The aging population in California will have a substantial impact on the U.S. onychomycosis market. The state’s 60-and-over population is predicted to reach 14.7 million by 2060, growing more than three times faster than the general population. With the number of Californians aged 65 and older expected to nearly double to 11.5 million by 2060, and onychomycosis affecting up to 50% of those over 70, the aging population represents a significant patient pool. The CDC’s estimate of 10-12% onychomycosis prevalence, combined with increased diabetes rates among older persons (13.8% affected), adds to the demand for therapies. This generational transition is driving significant market growth, emphasizing the need for both traditional and new onychomycosis treatment options in California.

Increased awareness is propelling the US Onychomycosis Market in California. The California Department of Public Health’s focus on fungal infections, combined with the 26,000 reported healthcare-associated infections in 2019, has increased public awareness of onychomycosis. With 72% of California adults visiting doctors for routine checks by 2021, opportunities for diagnosis and treatment talks have grown. The state’s expanding number of podiatrists, which is predicted to increase by 10% over the next five years, along with 79% of physicians’ usage of electronic health information, improves patient education and care management. Given that 10-14% of the US population may be afflicted, including up to 5.5 million Californians, greater awareness is considerably driving demand for both established and new therapies.

Competitive Landscape

The US onychomycosis market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the market include:

• Novartis AG
• Johnson & Johnson
• Pfizer, Inc.
• Galderma S.A.
• Bayer AG
• Valeant Pharmaceuticals International, Inc.
• GlaxoSmithKline plc
• Merz Pharma GmbH & Co. KGaA
• Reddy’s Laboratories Ltd.
• LEO Pharma A/S.

Latest Developments

• In December 2021, The American Podiatric Medical Association (APMA) approved Jublia, created by Bausch Health Companies Inc. In 2020, the FDA extended the drug’s approval to treat children and adult patients with onychomycosis.
• In July 2021, Lupin debuted Tavaborole, a generic topical solution, in the United States. The topical solution is equivalent to topical Kerydin, which is used to treat toenail onychomycosis caused by Trichophyton rubrum or Trichophyton mentagrophytes.
• In April 2021, Aleor Dermaceuticals gained FDA approval for efinaconazole topical solution to treat fungal toenail infections.

Report Scope

US Onychomycosis Market, By Category

Type:

• Distal Subungual Onychomycosis (DSO)
• White Superficial Onychomycosis (WSO)
• Proximal Subungual Onychomycosis (PSO)
• Endonyx Onychomycosis (EO)

Route of Administration:

• Oral
• Topical
• Surgical removal
• Laser therapy

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Channels

Region:

• New York
• Illinois
• Georgia
• California
• Washington

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.